The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Godefridus J. Peters

Dept. of Medical Oncology

VU University Medical Center

Cancer Center Amsterdam

De Boelelaan 1117



Name/email consistency: high



  • Dept. of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, Netherlands. 2002 - 2012


  1. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Erdem, L., Giovannetti, E., Leon, L.G., Honeywell, R., Peters, G.J. Curr. Top. Med. Chem (2012) [Pubmed]
  2. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Elnaggar, M., Giovannetti, E., Peters, G.J. Curr. Pharm. Des. (2012) [Pubmed]
  3. Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. Peters, G.J., Hodzic, J., Ortega, B., Giovannetti, E., Adema, A.D., Broekhuizen, R., Kaspers, G.J., Hubeek, I. Nucleosides. Nucleotides. Nucleic. Acids (2010) [Pubmed]
  4. Thymidine phoshorylase as a target for antiangiogenesis treatment. Peters, G.J., Bijnsdorp, I.V., Fukushima, M. Nucleic. Acids. Symp. Ser. (Oxf) (2008) [Pubmed]
  5. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. Peters, G.J., Clavel, M., Noordhuis, P., Geyssen, G.J., Laan, A.C., Guastalla, J., Edzes, H.T., Vermorken, J.B. J. Chemother (2007) [Pubmed]
  6. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Peters, G.J., Van Moorsel, C.J., Lakerveld, B., Smid, K., Noordhuis, P., Comijn, E.C., Weaver, D., Willey, J.C., Voorn, D., Van der Vijgh, W.J., Pinedo, H.M. Int. J. Oncol. (2006) [Pubmed]
  7. Purine and pyrimidine metabolism: a firm basis for a transformed society. Peters, G.J., Carrey, E.A., Sebesta, I. Nucleosides. Nucleotides. Nucleic. Acids (2006) [Pubmed]
  8. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. Peters, G.J., Smorenburg, C.H., Van Groeningen, C.J. J. Chemother (2004) [Pubmed]
  9. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Peters, G.J., Noordhuis, P., Van Kuilenburg, A.B., Schornagel, J.H., Gall, H., Turner, S.L., Swart, M.S., Voorn, D., Van Gennip, A.H., Wanders, J., Holwerda, U., Smid, K., Giaccone, G., Fumoleau, P., Van Groeningen, C.J. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  10. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Backus, H.H., Wouters, D., Ferreira, C.G., van Houten, V.M., Brakenhoff, R.H., Pinedo, H.M., Peters, G.J. Eur. J. Cancer (2003) [Pubmed]
  11. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Peters, G.J., Backus, H.H., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C.L., Smid, K., Lunec, J., Calvert, A.H., Marsh, S., McLeod, H.L., Bloemena, E., Meijer, S., Jansen, G., van Groeningen, C.J., Pinedo, H.M. Biochim. Biophys. Acta (2002) [Pubmed]
WikiGenes - Universities